Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it. The symptoms ...

Chronic constipation, often dismissed as a minor issue, can sometimes signal serious underlying conditions like colon, rectal ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

An MRI-based imaging technique developed at the University of Cambridge could be used to predict the response of ovarian ...

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in ...

A small drug developer in Research Triangle Park is working on a major funding round to support the development of a new ...

This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

New Castle County police officers, and members of Fraternal Order of Police Lodge #5, went above and beyond the call of duty ...

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

Russian experts claim to have developed a mRNA-based vaccine to treat cancer, which will be available for free to patients ...